Unknown Cancer NIHR-supported project Lungs & Breathing
CA244-0001: A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL B01D1)combinations in Adult Participants with Advanced Solid Tumors
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Alexandra Pender (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers(CA027002 )
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
BMS CA224-020 - A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know